Clinical Trial Update: Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma [Phase 2]

View source ↗

Summary

A Phase IIb trial of AP-12009, a TGF-β2 antisense oligonucleotide, for recurrent or refractory high-grade glioma including glioblastoma and anaplastic astrocyto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• AP-12009

Snippet

Sponsor: Isarna Therapeutics GmbH | Conditions: Glioblastoma, Anaplastic Astrocytoma | Phase 2 | Status: COMPLETED